Literature DB >> 17587647

Risk calculation for hyperkalaemia in heart failure patients.

T L J Vereijken1, L Bellersen, J M M Groenewoud, L Knubben, L Baltussen, C Kramers.   

Abstract

BACKGROUND: We aimed to develop a model to estimate the risk of hyperkalaemia in patients treated for heart failure in a tertiary reference hospital and to identify precipitating factors.
METHODS: 125 congestive heart failure (CHF) patients were studied retrospectively. Thirty of these patients developed episodes of hyperkalaemia (K>or=5.5 mmol/l). Both groups were compared for possible risk factors for hyperkalaemia (age, glomerular filtration rate (GFR), New York Heart Association (NYHA) class, diabetes mellitus (DM), ejection fraction and medication use (ACE inhibitors, angiotensin receptor blockers, aldosterone antagonists).
RESULTS: On multivariate logistic regression analysis DM (OR 2.9, 95% CI=1.05 to 8.3, p=0.041), GFR<45 ml/min (OR 4.1, 95% CI=1.6 to 10.5. p=0.004) and NYHA class III-IV (OR 2.4, 95% CI=0.9 to 6.3, p=0.086) were independently associated with hyperkalaemia, whereas age, ejection fraction and medication sort and dose were not. Of the episodes of hyperkalaemia, 38% were precipitated by periods of dehydration (diarrhoea, fever) or change of medication.
CONCLUSION: We identified kidney function, diabetes mellitus and heart failure class as independent risk factors of hyperkalaemia. The majority of the hyperkalaemic episodes develop without a precipitating factor. This implies that heart failure patients in a tertiary reference hospital should be very closely monitored to minimize the risk for hyperkalaemia.

Entities:  

Mesh:

Year:  2007        PMID: 17587647

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  4 in total

1.  [Life-threatening hyperkalemia due to a delayed hemolytic transfusion reaction].

Authors:  Lin Zhu; Sandra Schütze
Journal:  Z Gerontol Geriatr       Date:  2021-06-23       Impact factor: 1.281

2.  Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy.

Authors:  Giampiero Giovacchini; Guillaume Nicolas; Heike Freidank; Thomas L Mindt; Flavio Forrer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

3.  Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs.

Authors:  Esther V Uijtendaal; Jeannette E F Zwart-van Rijkom; Wouter W van Solinge; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2011-03-19       Impact factor: 2.953

4.  New treatments for hyperkalaemia: clinical use in cardiology.

Authors:  Shilpa Vijayakumar; Javed Butler; Stefan D Anker
Journal:  Eur Heart J Suppl       Date:  2019-02-26       Impact factor: 1.803

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.